CP 47,497 or (C7)-CP 47,497 is a

cannabinoid Cannabinoids () are several structural classes of compounds found in the cannabis plant primarily and most animal organisms (although insects lack such receptors) or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tet ...

receptor agonist drug, developed by

Pfizer Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...

in the 1980s. It has

analgesic An analgesic drug, also called simply an analgesic (American English), analgaesic (British English), pain reliever, or painkiller, is any member of the group of drugs used to achieve relief from pain (that is, analgesia or pain management). It ...

effects and is used in scientific research. It is a potent CB₁ agonist with a ''K''_d of 2.1 nM.

Homologue

On the 19th of January 2009, the University of Freiburg in Germany announced that an

analog Analog or analogue may refer to: Computing and electronics * Analog signal, in which information is encoded in a continuous variable ** Analog device, an apparatus that operates on analog signals *** Analog electronics, circuits which use analog ...

of CP 47,497 is the main active ingredient in the herbal "incense" product

Spice A spice is a seed, fruit, root, bark, or other plant substance primarily used for flavoring or coloring food. Spices are distinguished from herbs, which are the leaves, flowers, or stems of plants used for flavoring or as a garnish. Spices a ...

, specifically the 1,1-dimethyloctyl homologue of CP 47,497. Both the dimethylheptyl and dimethyloctyl homologues were detected in different batches, with considerable variation in the concentration present in different samples that were analysed. The weaker dimethylhexyl and dimethylnonyl homologues were not found in any batches of smoking blends tested, but have been legally scheduled alongside the others in some jurisdictions, to forestall any potential use for this purpose. The 1,1-dimethyloctyl homologue of CP 47,497 is several times more potent than the parent compound, which is somewhat unexpected as the 1,1-dimethylheptyl is the most potent substituent in classical cannabinoid compounds such as

HU-210 HU-210 is a synthetic cannabinoid that was first chemical synthesis, synthesized in 1988 from (1R,5S)-myrtenol by a group led by Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural Tetrahydrocannabinol, ...

. The unapproved use of these compounds in herbal smoking blends has led to a resurgence in legitimate scientific research into their use, and consequently the C8 homologue of CP 47,497 has been assigned a proper name,

cannabicyclohexanol Cannabicyclohexanol (CCH, CP 47,497 dimethyloctyl homologue, (C8)-CP 47,497) is a cannabinoid receptor agonist drug, developed by Pfizer in 1979. On 19 January 2009, the University of Freiburg in Germany announced that an analog of CP 47,497 was ...

Legal status

Germany

On 22 January 2009, CP 47,497 was added to the German controlled drug schedules ("Betäubungsmittelgesetz"), along with its dimethylhexyl, dimethyloctyl and dimethylnonyl homologues.BGBl I Nr. 3 vom 21.01.2009, 22. BtMÄndV vom 19. Januar 2009, S. 49–50

France

CP 47,497 and its C6, C8, and C9 homologues were made illegal in France on 24 February 2009.

Latvia

CP 47,497 and its C6, C8, and C9 homologues were made illegal in Latvia on 28 November 2009.

Lithuania

CP 47,497 and its C6, C8, and C9 homologues were made illegal in Lithuania on 5 June 2009.

Sweden

CP 47,497 and its C6, C7, C8, and C9 homologues were made illegal in Sweden on 15 September 2009.

Romania

CP 47,497 and its C6, C7, C8, and C9 homologues were made illegal in Romania on 15 February 2010.(

United States

As of March 1, 2011, it is a schedule 1 drug.

References

{{DEFAULTSORT:Cp 47,497 Cyclohexanols Cannabinoids Designer drugs Pfizer brands Phenols Alkyl-substituted benzenes CB1 receptor agonists